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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S388that a worse VPT was associated with signiﬁcantly more rapid loss of
JSW of the lateral ankle joint (Pearson’s r¼0.37, p¼0.03). No signiﬁcant
relationship was observed between VPT and change in medial ankle
joint space width (Pearson’s r¼0.27, p¼0.12).
Conclusion: In patients with medial knee OA but no intrinsic foot dis-
ease, worse VPT at baseline is associated with more rapid narrowing of
JSW in ankles laterally. This suggests that these subjects function with
the foot and anklemore towards themidline of the body with the ankle/
subtalar joint complex everting to allow for foot compensation. This is
consistent with current theories that those with medial knee OA have a
more varus attribute to the lower leg and foot. Mechanistic studies are
needed to determine whether rearfoot varus compensation is produc-
ing excessive valgus loads across the ankle joint leading to joint space
narrowing.
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SUSTAINABILITY OF EFFECTS OF LAND-BASED EXERCISE ON PAIN
AND PHYSICAL FUNCTION FOR OSTEOARTHRITIS OF THE KNEE:
SYSTEMATIC REVIEW AND META-ANALYSIS
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Purpose: To determine whether effects of therapeutic land-based
exercise on self-reported pain and physical function are sustainable
among patients with knee osteoarthritis (OA).
Methods: A systematic review and meta-analysis was conducted. Five
databases were searched from their inception until May 2013. All
randomised controlled trials (RCTs) recruiting people with knee OA and
comparing some form of land-based therapeutic exercise (as opposed to
exercises conducted in thewater) with a non-exercise or non-treatment
(or waiting list) intervention were included. Programs could be
designed and supervised by physiotherapists or other professionals, or
provided as a home program with minimal monitoring. Studies that
compared one type of exercise program to another exercise program,
provided an exercise program to all treatment allocations (and eval-
uated the added beneﬁt of an electrophysical agent, prescribed drug or
hydrotherapy), compared exercise with manual therapy, provided all
study participants with a ﬁxed dose of NSAIDs throughout the study
period, or compared programs of varying intensities, were excluded.Three teams, each comprising two review authors, independently
screened the selected studies for inclusion (33% of the retrieved studies
screened per team). Disagreements were resolved through consensus,
or, if no agreement could be reached, a ﬁnal determinationwasmade by
the lead author (MF). Each team assessed another team’s included
studies and conﬁrmed suitability for inclusion, after which data were
extracted and methodological quality assessed. We assessed the risk of
bias according to the following domains: random sequence generation,
allocation concealment, blinding of participants and personnel, blind-
ing of outcome assessment, handling of incomplete outcome data
(intention to treat analysis) and selective outcome reporting (evidence
of trial registration). Studies were considered to have an overall low risk
of bias if four of the six criteria were met. All analyses were conducted
on continuous outcomes. Results were pooled using standardised mean
differences (SMD) and a random effects model to calculate treatment
effect sizes from either the change scores from baseline to follow-up
(deﬁned as 6 weeks to 6 months after the cessation of monitored
treatment) or from the follow-up score alone, and their respective
standard deviation (SD) scores.
Results: Of the 60 included RCTs, 15 studies (1,908 participants) pro-
vided sustainability data for pain and 14 studies (1875 participants)
provided sustainability data for self-reported physical function. The
mean follow-up time (after the cessation of the intervention) of the
included studies was 3.3 (SD 1.4) months. There were marked differ-
ences between the included studies in treatment delivery mode; nine
evaluated supervised class-based exercise, four evaluated home exer-
cise programs with varying levels of monitoring, while two evaluated
exercise therapy provided individually to the patient by a
physiotherapist.
Pooling the results demonstrated that the reduction in knee pain
afforded by land-based exercise therapy was sustained 6 weeks to 6
months after the cessation of therapy, with an SMD of -0.24 (95% CI
-0.13 to -0.36); heterogeneity (I2) ¼ 28%. Similarly, the improvement in
physical functionwith exercise therapy was sustained at follow-up with
an SMD of -0.18 (95% CI -0.08 to -0.27); heterogeneity was negligible, I2
¼ 9%. Restricting the pooled analyses to the nine RCTs (1,482 partic-
ipants) evaluated as having a low risk of bias does not markedly change
the results for pain (SMD -0.23 (95% CI -0.07 to -0.38), I2 ¼ 50%) or for
self-reported physical function (SMD -0.20 (95% CI -0.09 to -0.30), I2 ¼
0%).
Conclusions: The positive effects of mostly class or home-based ther-
apeutic exercise on self-reported pain and physical function among
people with symptomatic knee OA are sustained at least 6 weeks to 6
months after the cessation of the monitored program.
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Purpose: A higher bodymass index (BMI) is a risk factor for progression
of structural damage in osteoarthritis (OA) of the knee. Wewould like to
investigate if this same relationship is present in patients with hand OA.
Our aim was to study the association between BMI in early adulthood
and development of hand OA as well as the relation between BMI and
development of OA in joints previously unaffected in patients with
established hand OA.
Methods: In total 176 participants (161 women, mean (SD) age 61.5
(5.8) years) from the Oslo hand OA cohort underwent a baseline
examination in 2001-03, of whom 104 attended a follow-up examina-
tion in 2008-09. At both time points, they underwent measurements of
height and weight (used for BMI calculation kg/ m2) and conventional
hand radiographs. They also completed a questionnaire, inwhich height
and weight at the age of 25 years were self-reported. The distal and
proximal interphalangeal, metacarpophalangeal and ﬁrst carpometa-
carpal joints in both hands were scored according the Kellgren-Law-
rence scale (grade 0-4). Mild hand OAwas deﬁned as Kellgren-Lawrence
grade (KLG) 2, whereasmoderate/severe hand OAwas deﬁned as KLG 3-
4. First, we examined the association between BMI and incident hand
OA during the period from 25 years of age to the baseline examination,
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examined the association between baseline BMI and incident hand OA
at follow-up (in joints free of hand OA at baseline). Analyses were
adjusted for age and sex and were performed by generalized estimating
equation (GEE) to account for within patient dependency. All analyses
were repeated using change in BMI as the predictor variable with
additional adjustment for BMI and follow-up time.
Results: Mean (SD) baseline BMI was 20.9 (2.2) kg/m2 at the age of 25
years, 25.6 (4.1) kg/m2 at the baseline examination, and 26.2 (3.7) kg/m2
at follow-up. At baseline, 566 (10.8%) joints had mild OA and 485 (9.2 %)
had moderate/severe OA. There was no signiﬁcant association between
BMI at 25 years of age and incident OA at the baseline examination
(Table), nor was there any association between BMI change from 25
years of age to baseline incident OA. In joints free of OA at the baseline
examination, 150 (6.2%) joints had incident mild OA and 118 (4.9%) had
incident moderate/severe OA at follow-up. There was no association
between baseline BMI or change in BMI between baseline and follow-up
(mean (SD) follow-up time 7.3 (0.6) years) and incident OA at follow-up
(Table). Similar strength of associations for mild and moderate/severe
OA indicates no association between BMI and rapid OA progression.
Conclusions: In the Oslo hand OA cohort, no association was observed
between self-reported BMI in early adulthood and later development of
hand OA. Similarly, we found no association between BMI and devel-
opment of hand OA in joints previously unaffected in patients with
established disease over a 7-year follow-up.Table: Associations between BMI and incident hand OA (analyses at joint level)
Incident hand OA (KLG¼2) or (95% CI) Incident hand OA (KLG¼3-4) or (95% CI)
Associations between BMI and incident hand OA at baseline (2001-03) *
BMI at 25 years of age 0.99 (0.92, 1.07) 1.09 (0.99, 1.20)
Change in BMI from 25 years to baseline 1.00 (0.96, 1.03) 1.01 (0.93, 1.08)
Associations between BMI and incident hand OA at follow-up (2008-09) **
BMI at baseline 1.02 (0.97, 1.06) 1.01 (0.93, 1.09)
Change in BMI from baseline to follow-up 0.95 (0.85, 1.06) 0.93 (0.81, 1.06)
*n¼5248 joints (from 176 patients) included in the analyses assuming no OA at the age of 25 years.
**n¼2494 joints (from 104 patients) with KLG 0-1 at baseline included in the analyses, 604 joints with KLG 2-4 were excluded. OR¼odds ratio, CI¼conﬁdence interval.691
PAIN, FUNCTION, QUALITY OF LIFE AND PHYSICAL ACTIVITY IN
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Purpose: Little is known about how osteoarthrtitis (OA) in the tibio-
femoraljoint (TF) and patellofemoraljoint (PF) differ in symptoms and
function. This cross-sectional study aimed to describe differences in
self-reported pain, symptoms, physical function, health related quality
of life (HRQL) and physical activity (PA) in persons with radiographic TF-
and/or PF OA or no radiographic OA.
Methods: 121 persons (45% women) from an ongoing populationbased
cohort study with chronic knee pain at inclusion (The Spenshult
cohort), mean age 64,5 years. 105 persons had radiographic examina-
tions and were included in the present study. Radiographic TF OA was
deﬁned as a joint spacewidth (JSW)< 3mm and PF OA< 5mm. Pain and
physical function were assessed using Knee injury and Osteoarthritis
Outcome Score (KOOS) and HRQL using EQ-5D. PA was estimated as
proportion of patients accumulating 150 activity minutes per week on
moderate intensity. Kruskal-Wallis test was used to compare groups for
pain, physical function, HRQL, age and Body Mass Index (BMI). Mann-
Whitney U-test was used for the post-hoc analysis (p-values <0,01).
Results: 49 persons (47%) had no OA according to JSW (no OA), 33 (31%)
had PF OA (PF), 16 (15%) had TF OA (TF) and 7 (7%) had both TF and PF OA
(TFþPF). There were signiﬁcant differences between groups in HRQL
(p¼0,009), KOOS pain (p¼0,023), KOOS symptoms (p¼0,017), KOOS
function in daily living (p¼0,029) and KOOS Sport/recreation (p¼0,002).
No signiﬁcant difference was found between groups in accumulating
150 activity minutes/week (proportion range from 57 to 90%, p¼0,13).TFþPF group reported signiﬁcant more pain, worse kneefunction and
worse HRQL.
Conclusions: PF OA is common. Persons with TFþPF OA reported worse
symptoms and HRQL. Further studies are needed to identify prognostic
factors for OA symptom development. Early preventive initiatives could
possibly prevent deterioration of symptoms.
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S. Colen y, M. van Rijen z, S. Plomp z, L. Creemers z. yUniv. Hosp. Leuven,
Leuven, Belgium; zUniv. Med. Ctr. Utrecht, Utrecht, Netherlands
Abstract
Purpose: Corticosteroids (CS) are used for several treatments including
intra-articular treatment of osteoarthritis. However, these can have
severe side-effects, especially if patients have to be treated several times
in the same joint. Applying CS in a controlled releasemanner (CS applied
in microspheres (MS)), can possibly reduce the number of injections
with CS needed and also prevent side-effects. The aim of this in vitro
study is to show the efﬁcacy of MS loadedwith CS on humanTNF-alpha-
stimulated osteoarthritic (OA) chondrocytes in an in vitro model.
Methods: TNF-alpha stimulated OA chondrocytes from three human
donors were incubated in the presence of MS loaded with 5 wt% of
triamcinolone acetonide (TAA). MS were added to transwells atamounts estaimted to release in total 1x10-7 M TAA/3 days. Every three
days the cells and medium were collected and the transwells were
transferred to wells with freshly plated and stimulated OA chon-
drocytes. The total duration of the tests was 28 days. As controls we
used non-stimulated chondrocytes and TNF-alpha-stimulated OA
chondrocytes cultured in the presence of a bolus of 1x10-7 mol TAA and
empty (without TAA) MS. The bioactivity of the TA released from the
loaded MS was tested using PGE2 production as an outcome parameter
of inﬂammation (using PGE2 ELISA).
Results: Because of the large ﬂuctuation of the levels of PGE2 at the
different time points in the TNF-alpha-stimulated cells, all levels of
PGE2 determined in the treatment and control groups were divided by
the level of PGE2 in the TNF-alpha-stimulated cells (table 1). The PGE2-
level in the cells treated with a bolus of 1x10-7 mol TAA reached a
maximum of 4.6%. The highest percentage of PGE2 in the MS loaded
with 1x10-7 mol TAA/3 days group was 5.2% at time-point 8 (28 days
follow-up) (table 2). Although the levels of PGE2 in the empty MS and
non-TNF-alpha-stimulated cells compared to the negative control and
the levels of PGE2 in the empty MS and TNF-alpha-stimulated cells
compared to TNF-alpha-stimulated cells, seem to be higher at the ﬁrst
time point(s), this difference is never signiﬁcant. The levels of PGE2 in
the empty MS and non-TNF-alpha-stimulated cells compared to the
negative control and the levels of PGE2 in the emptyMS and TNF-alpha-
stimulated cells compared to TNF-alpha-stimulated cells showed no
signiﬁcant differences indicating that the MS are not causing any
additional inﬂammation (table 3 and 4).
Conclusions: This study showed that MS loaded with TAA signiﬁcantly
reduce inﬂammation in TNF-alpha induced OA chondrocytes over a
period of at least 28 days. The slow-release platform using MS loaded
with TAA in this study showed in vitro promising results for long term
inhibition of inﬂammation. In vivo studies (still in testing phase)
showed presence of intra-articular MS (using optical imaging) at least 8
weeks after intra-articular injection in a knee of a rat.
